Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | F13A1 | P00488 | 4/20 | 0.47 |
| ▸ | TGM1 | P22735 | 4/20 | 0.47 |
| ▸ | TGM6 | O95932 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14057747 | 0.94 | TGM2 (0.50) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14055348 | 0.93 | NPC1 (0.50) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14055903 | 0.91 | TGM2 (0.53) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14055363 | 0.91 | TGM2 (0.58) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14056853 | 0.91 | TGM2 (0.53) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14054701 | 0.89 | MMP2 (0.47) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14056518 | 0.88 | TGM2 (0.55) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL14056471 | 0.86 | MMP2 (0.47) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14054249 | 0.86 | KDM1A (0.46) | TGM2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL14055321 | 0.86 | KDM1A (0.44) | TGM2NPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | TGM2 2/4885NPC1 2123/4885RAB9A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.